Vaxart announced publication of the preclinical results of its oral F-protein based respiratory syncytial Virus, or RSV-F, vaccine. The findings were published in the most recent online version of Vaccine. As described in the article, the oral RSV-F vaccine candidate provided complete sterilizing protection against RSV infection in the cotton rat challenge model at the target dose. The vaccine induced significant and dose-dependent neutralizing antibody responses in serum, as well as multi-functional effector and memory B cell responses at the mucosal surface along the respiratory tract. Importantly, the Vaxart oral RSV-F vaccine did not cause any inflammatory pathology in the respiratory tract.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.